Peer-reviewed publications and citation record
Peer-reviewed research spanning cell therapy, tissue engineering, targeted drug delivery, oncology and quantitative modeling.
Research · Writing · Media
Evidence, ideas & conversations.
A selected record of peer-reviewed research, authored commentary, scientific explainers, interviews and independent coverage across biotechnology, medicine, markets and society.
Peer-reviewed research
A scientific record spanning cell therapy, tissue engineering, drug delivery and translational biotechnology.
Authored writing & commentary
Perspectives on biotechnology, innovation, intellectual property, markets and public health.
Biotech 2024: Opportunities and challenges for Israeli companies
An assessment of the market conditions affecting Israeli biotechnology companies and the investment opportunity created by sector-wide undervaluation.
More context
The article connects strong clinical programs with constrained capital markets, arguing that development maturity and depressed valuations can create selective opportunities.
From the Da Vinci Code to the genetic code: Innovation and challenges in biotechnology patents
A practical examination of how biotechnology patents support innovation while creating strategic, financial and ethical trade-offs.
More context
Co-authored with patent attorney Dr. Assaf Gara, the article considers geographic protection, development timelines, access and the role of trade secrets in advanced therapies.
Imitate nature or wait for nature? Two approaches shaping the medicine of tomorrow
A comparison of two tissue-engineering philosophies: constructing biology directly or creating conditions that allow natural regenerative processes to work.
More context
Using BonoFill as a practical example, the article examines living grafts, bioprinting and the balance between engineering control and biological complexity.
COVID: The end of the beginning
An argument that the transition from pandemic to endemic COVID did not remove the need for effective treatments for severe and critical patients.
More context
The article focuses on respiratory failure, health-system burden and the continuing role of therapies that address inflammation, pneumonia and tissue damage.
Scientific explainers & produced media
Visual storytelling that makes advanced therapeutic platforms accessible without losing the underlying science.
NanoGhosts: Targeted drug delivery using cell-derived nanovesicles
Concept development · Scientific narrative · Script · Production leadership
A visual explanation of how cell-derived nanovesicles preserve the natural targeting capabilities of mesenchymal stromal cells while carrying therapeutic payloads.
More context
Created during Tomer’s Technion years, the film translates the platform’s cell-derived targeting mechanism into an accessible visual story.
Bonus BioGroup: Building living therapies
Concept development · Scientific narrative · Script · Production leadership
A company-level introduction to the science, development vision and human purpose behind Bonus BioGroup’s cell-therapy and tissue-engineering programs.
More context
The film presents the company’s broader advanced-therapy portfolio and development vision across cell therapy and tissue engineering.
MesenCure: Cell therapy for severe respiratory distress
Concept development · Scientific narrative · Script · Production leadership
A visual account of how primed mesenchymal stromal cells are designed to sense inflammatory injury and support immune modulation and tissue repair.
More context
The film explains therapeutic priming and the cellular response to inflammatory lung injury for scientific and non-specialist audiences.
Podcasts & interviews
Conversations about advanced cell therapies, clinical evidence and the path from science to patients.
Episode 22: Dr Tomer Bronshtein — Innovative cell therapies
A long-form discussion of MesenCure, acute respiratory distress and the potential relationship between effective early treatment and Long COVID.
More context
The conversation covers the therapy’s mechanism, clinical findings, future applications and the caution required when interpreting emerging cell-therapy evidence.
MesenCure interview on i24 News
A broadcast interview discussing MesenCure and the clinical implications of its Phase II results in severe COVID-19.
More context
The discussion translates the treatment’s cell-based mechanism and reported outcomes for a general international news audience.
Interview on MesenCure cell therapy
A Hebrew-language interview explaining MesenCure’s therapeutic rationale and development for severe COVID-19.
More context
The segment presents the science behind the cell therapy and its intended role in reducing harmful inflammation and respiratory distress.
Independent media coverage
Selected reporting featuring interviews and commentary on MesenCure and cell-based therapeutics.
Israeli company’s COVID-19 drug shows promise in late-stage coronavirus treatment
Fox News reporting on MesenCure’s Phase II results, including an interview with Tomer Bronshtein about survival, hospitalization and mechanism of action.
More context
The article places the clinical data in the context of late-stage COVID treatment and explains how the living-cell therapy responds to lung inflammation.
Israeli cell-based drug offers hope against COVID-19 variants
An in-depth feature on how MesenCure’s primed mesenchymal stromal cells respond to inflammation across emerging COVID-19 variants.
More context
The article includes extensive commentary from Tomer Bronshtein on cell education, cytokine storm, treatment sophistication and the broader promise of cell therapy.
Continue the conversation